TY - JOUR
T1 - Cell Origin and iNOS Function Are Critical to Macrophage Activation Following Acute Lung Injury
AU - Golden, Thea N.
AU - Venosa, Alessandro
AU - Gow, Andrew J.
N1 - Funding Information:
NIH Funding: GM108463 (TNG), ES007148 (TNG), ES019851 (TNG), ES032553 (AV), HL086621 (AJG), ES5005022 (AJG). Society for Redox Biology and Medicine Mini-Fellowship Grant (TNG) and Society of Toxicology Supplemental Training for Education Program (TNG).
Publisher Copyright:
Copyright © 2022 Golden, Venosa and Gow.
PY - 2022/1/25
Y1 - 2022/1/25
N2 - In the intratracheal bleomycin (ITB) model of acute lung injury (ALI), macrophages are recruited to the lung and participate in the inflammation and resolution that follows injury. Macrophage origin is influential in determining activation; however, the specific phenotype of recruited and resident macrophages is not known. Inducible nitric oxide synthase (iNOS) has been implicated in the pathogenesis of ALI; however, the effects of its inhibition are mixed. Here we examined how macrophage origin determines the phenotypic response to ALI. Further, we hypothesize cell specific iNOS is key to determining activation and recruitment. Using a chimeric mouse approach, we have identified recruited and resident macrophage populations. We also used the chimeric mouse approach to create either pulmonary or bone marrow NOS2−/− mice and systemically inhibited iNOS via 1400 W. We evaluated macrophage populations at the peak of inflammation (8 days) and the beginning of resolution (15 days) following ITB. These studies demonstrate tissue resident macrophages adopt a M2 phenotype specifically, but monocyte originated macrophages activate along a spectrum. Additionally, we demonstrated that monocyte originating macrophage derived iNOS is responsible for recruitment to the lung during the inflammatory phase. Further, we show that macrophage activation is dependent upon cellular origin. Finally, these studies suggest pulmonary derived iNOS is detrimental to the lung following ITB. In conclusion, macrophage origin is a key determinant in response to ALI and iNOS is central to recruitment and activation.
AB - In the intratracheal bleomycin (ITB) model of acute lung injury (ALI), macrophages are recruited to the lung and participate in the inflammation and resolution that follows injury. Macrophage origin is influential in determining activation; however, the specific phenotype of recruited and resident macrophages is not known. Inducible nitric oxide synthase (iNOS) has been implicated in the pathogenesis of ALI; however, the effects of its inhibition are mixed. Here we examined how macrophage origin determines the phenotypic response to ALI. Further, we hypothesize cell specific iNOS is key to determining activation and recruitment. Using a chimeric mouse approach, we have identified recruited and resident macrophage populations. We also used the chimeric mouse approach to create either pulmonary or bone marrow NOS2−/− mice and systemically inhibited iNOS via 1400 W. We evaluated macrophage populations at the peak of inflammation (8 days) and the beginning of resolution (15 days) following ITB. These studies demonstrate tissue resident macrophages adopt a M2 phenotype specifically, but monocyte originated macrophages activate along a spectrum. Additionally, we demonstrated that monocyte originating macrophage derived iNOS is responsible for recruitment to the lung during the inflammatory phase. Further, we show that macrophage activation is dependent upon cellular origin. Finally, these studies suggest pulmonary derived iNOS is detrimental to the lung following ITB. In conclusion, macrophage origin is a key determinant in response to ALI and iNOS is central to recruitment and activation.
KW - iNOS inhibition
KW - macrophage activation
KW - macrophage phenotype
KW - pulmonary inflammation
KW - pulmonary injury
UR - http://www.scopus.com/inward/record.url?scp=85124254582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124254582&partnerID=8YFLogxK
U2 - 10.3389/fphar.2021.761496
DO - 10.3389/fphar.2021.761496
M3 - Article
AN - SCOPUS:85124254582
SN - 1663-9812
VL - 12
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 761496
ER -